Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13602319 | 0.85 | KDM4E (0.53) | KDM4EMAPTALDH1A1TDP1CHRNA4 | |
| SCHEMBL13648205 | 0.84 | KDM4E (0.49) | CD44KDM4EALDH1A1TDP1CHRNA4 | |
| SCHEMBL13696489 | 0.81 | KDM4E (0.49) | KDM4EMAPTALDH1A1TDP1CHRNA4 | |
| SCHEMBL14291307 | 0.81 | KDM4E (0.45) | KDM4EMAPTROCK2ALDH1A1TDP1 | |
| SCHEMBL13653261 | 0.79 | UTS2R (0.47) | KDM4EMAPTROCK2ALDH1A1CHRNA4 | |
| SCHEMBL16372582 | 0.78 | KDM4E (0.53) | KDM4EMAPTROCK2ALDH1A1TDP1 | |
| SCHEMBL13648211 | 0.78 | PDK2 (0.40) | CD44KDM4EMAPTALDH1A1TDP1 | |
| SCHEMBL13602320 | 0.77 | CYP1A2 (0.47) | KDM4EALDH1A1TDP1GAACYP1A2 | |
| SCHEMBL13663257 | 0.76 | KDM4E (0.50) | KDM4EMAPTALDH1A1TDP1CHRNA4 | |
| SCHEMBL5368370 | 0.75 | KDM4E (0.55) | KDM4EMAPTROCK2ALDH1A1CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1720846-A1 | USE OF THIADIAZOLE UREA DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005085220-A1 | USE OF THIADIAZOLE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MAP3K1, MAP3K6, MAP3K2 | CD44 4728/4885KDM4E 1349/4885MAPT 2963/4885 |
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | RAF1, ARAF, JAK1 | CD44 4761/4885KDM4E 4039/4885MAPT 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.